C. De Nuccio

Dr. C. De Nuccio


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
RSRoberta De De Simone
Roberta De De Simone
FVFederica Vissicchio
Federica Vissicchio
CMCecilia Mingarelli
Cecilia Mingarelli
CNC. De Nuccio
C. De Nuccio
SVSergio Visentin
Sergio Visentin
LMLuisa Minghetti
Luisa Minghetti

30 July 2010 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
RSRoberta De De Simone
Roberta De De Simone
CNCristina Elena Niturad
Cristina Elena Niturad
CNC. De Nuccio
C. De Nuccio
MAMaria Antonietta Ajmone‐Cat
Maria Antonietta Ajmone‐Cat
SVSergio Visentin
Sergio Visentin
LMLuisa Minghetti
Luisa Minghetti

1 October 2011 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Closed access
PDF file
CNC. De Nuccio
C. De Nuccio
ABAntonietta Bernardo
Antonietta Bernardo
RSRoberta De De Simone
Roberta De De Simone
EMEnrico Mancuso
Enrico Mancuso
Valerio MagnaghiValerio Magnaghi
Valerio Magnaghi
LMLuisa Minghetti
Luisa Minghetti
We have previously shown that natural (15-deoxy-Δ12,14-prostaglandin J2) and synthetic (pioglitazone) agonists of peroxisome proliferator-activated receptor γ (PPAR-γ) strengthen the intrinsic cellular mechanisms protecting oligodendrocyte (OL) progenitors (OPs) from oxidative insults and promote their differentiation. Here, we demonstrate that repeated administrations of PPAR-γ agonists to OP cultures accelerate their differentiation to OLs, as indicated by increased numbers of O4- and O1-positive cells that show increased myelin basic protein expression, elaborated cholesterol-enrichedmembranes and have increased peroxisomes. Moreover, PPAR-γ agonist-treated OLs show increased activity of the mitochondrial respiratory chain Complex IV and an increased ability to respond to environmental signals, such as adenosine diphosphate (ADP), with oscillatory Ca2+ waves; the latter closely correlated with the presence of mitochondria and were inhibited by the mitochondrial respiratory chain Complex I inhibitor rotenone. Because Ca2+ oscillations and mitochondrial respiratory chain activity play crucial roles in OL differentiation, these findings suggest that PPAR-γ agonists could protect OLs and promote myelination through several mechanisms, including those involving mitochondrial functions. Our studies support the therapeutic potential of PPAR-γ agonists in brain diseases in which mitochondrial alteration, oxidative stress, and demyelination occur and point to the need for a better understanding of the role of PPAR-γ and its agonists in OL biology.

9 February 2012 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ALAngela Lanciotti
Angela Lanciotti
MBMARIA STEFANIA BRIGNONE
MARIA STEFANIA BRIGNONE
PMpaola molinari
paola molinari
SVSergio Visentin
Sergio Visentin
CNC. De Nuccio
C. De Nuccio
EAElena Ambrosini
Elena Ambrosini
Megalencephalic leukoencephalopathy with subcortical cysts (MLC), a rare leukodystrophy characterized by macrocephaly, subcortical fluid cysts and myelin vacuolation, has been linked to mutations in the MLC1 gene. This gene encodes a membrane protein that is highly expressed in astrocytes. Based on MLC pathological features, it was proposed that astrocyte-mediated defects in ion and fluid homeostasis could account for the alterations observed in MLC-affected brains. However, the role of MLC1 and the effects of pathological mutations on astrocyte osmoregulatory functions have still to be demonstrated. Using human astrocytoma cells stably overexpressing wild-type MLC1 or three known MLC-associated pathological mutations, we investigated MLC1 involvement in astrocyte reaction to osmotic changes using biochemical, dynamic video imaging and immunofluorescence techniques. We have found that MLC1 overexpressed in astrocytoma cells is mainly localized in the plasma membrane, is part of the Na,K-ATPase-associated molecular complex that includes the potassium channel Kir4.1, syntrophin and aquaporin-4 and functionally interacts with the calcium permeable channel TRPV4 (transient receptor potential vanilloid-4 cation channel) which mediates swelling-induced cytosolic calcium increase and volume recovery in response to hyposmosis. Pathological MLC mutations cause changes in MLC1 expression and intracellular localization as well as in the astrocyte response to osmotic changes by altering MLC1 molecular interactions with the Na,K-ATPase molecular complex and abolishing the increase in calcium influx induced by hyposmosis and treatment with the TRPV4 agonist 4αPDD. These data demonstrate, for the first time, that MLC1 plays a role in astrocyte osmo-homeostasis and that defects in intracellular calcium dynamics may contribute to MLC pathogenesis.

1 September 2017 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
ABAntonietta Bernardo
Antonietta Bernardo
MGM.L. Giammarco
M.L. Giammarco
CNC. De Nuccio
C. De Nuccio
MAM.A. Ajmone-Cat
M.A. Ajmone-Cat
SVSergio Visentin
Sergio Visentin
LMLuisa Minghetti
Luisa Minghetti

12 November 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GBGianfranco Balboni
Gianfranco Balboni
ILIlaria Lazzari
Ilaria Lazzari
CTClaudio Trapella
Claudio Trapella
LNLucia Negri
Lucia Negri
Roberta LattanziRoberta Lattanzi
Roberta Lattanzi
SSSevero Salvadori
Severo Salvadori